CoChat

Microbiome-derived ethanol in nonalcoholic fatty liver disease

Open access

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

To test the hypothesis that the gut microbiota of individuals with nonalcoholic fatty liver disease (NAFLD) produce enough ethanol to be a driving force in the development and progression of this complex disease, we performed one prospective clinical study and one intervention study. Ethanol was measured while fasting and 120 min after a mixed meal test (MMT) in 146 individuals. In a subset of 37 individuals and in an external validation cohort, ethanol was measured in portal vein blood. In an intervention study, ten individuals with NAFLD and ten overweight but otherwise healthy controls were infused with a selective alcohol dehydrogenase (ADH) inhibitor before an MMT. When compared to fasted peripheral blood, median portal vein ethanol concentrations were 187 (interquartile range (IQR), 17-516) times higher and increased with disease progression from 2.1 mM in individuals without steatosis to 8.0 mM in NAFL 21.0 mM in nonalcoholic steatohepatitis. Inhibition of ADH induced a 15-fold (IQR,1.6- to 20-fold) increase in peripheral blood ethanol concentrations in individuals with NAFLD, although this effect was abolished after antibiotic treatment. Specifically, Lactobacillaceae correlated with postprandial peripheral ethanol concentrations (Spearman's rho, 0.42; P < 10-5) in the prospective study. Our data show that the first-pass effect obscures the levels of endogenous ethanol production, suggesting that microbial ethanol could be considered in the pathogenesis of this highly prevalent liver disease.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02016-6

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 48 references

Cited by

See all 215

Metadata

Authors
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dirinck, E., Weyler, J., Verrijken, A., De Block, C. E. M., Vonghia, L., Francque, S., Beuers, U., Gerdes, V. E. A., Bäckhed, F., Groen, A. K., & Nieuwdorp, M.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • University of Gothenburg (SE)
  • Spaarne Ziekenhuis (NL)
  • Amsterdam University Medical Centers (NL)
  • Leiden University Medical Center (NL)
  • University of Copenhagen (DK)
  • Chalmers University of Technology (SE)
  • Antwerp University Hospital (BE)
Corresponding author
Nieuwdorp, Max
Venue
Nature Medicine
Published
2022-10
Volume
28
Issue
10
Pages
2100-2106
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4304080702
Cited by
215
References
49
Citations by year
2026: 40 · 2025: 57 · 2024: 56 · 2023: 55 · 2022: 5
FWCI
14.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
  • Chalmers Research (Chalmers University of Technology) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Gilead Sciences
  • Health~Holland
  • Amsterdam University Medical Centers (09150182010020)
  • European Foundation for the Study of Diabetes
  • ZonMw ([09150182010020], 17CVD01, 2019.82.004)
  • Diabetes Fonds (2019.82.004)
  • Fonds Wetenschappelijk Onderzoek (1802154N)
  • Novo Nordisk Fonden (NNF15SA0018346, NNF15OC0016798, 09150182010020)
  • Vlaamse regering
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, endogenous ethanol production, first-pass metabolism, alcohol dehydrogenase inhibition, antibiotic therapy, Lactobacillaceae, disease progression
MeSH terms
Alcohol Dehydrogenase, Ethanol, Anti-Bacterial Agents, Humans, Liver, Prospective Studies, Microbiota, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microbiome-derived ethanol in nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1038/s41591-022-02016-6
The paper
Meijnikman, A. S., Davids, M., Herrema, H., Aydin, O., Tremaroli, V., Rios-Morales, M., Levels, H., Bruin, S., de Brauw, M., Verheij, J., Kemper, M., Holleboom, A. G., Tushuizen, M. E., Schwartz, T. W., Nielsen, J., Brandjes, D., Dirinck, E., Weyler, J., Verrijken, A., . . . Nieuwdorp, M. (2022). Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nature Medicine. https://doi.org/10.1038/s41591-022-02016-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.